Allergan will eliminate about 5.5 percent of its workforce as part of a cost-cutting move while it prepares for generic competition on several lucrative drugs.
The company will cut 1,000 jobs and leave another 400 open positions unfilled. The Dublin-based company has about 18,000 employees.
Allergan expects restructuring costs of about $125 million and savings of $300 million to $400 million.
The company will likely face generic competition for its dry-eye drug Restasis, which helped boost revenue for eye care products by 4.4 percent to $635.5 million during the third quarter. A federal judge ruled against Allergan in a patent dispute in 2017 and the company reported a $3.2 billion charge following the loss.
Allergan is also expected to face generic competition for its Alzheimer's drug Namenda.